In contrast, we found limited evidence for heterogeneity in other clinical outcomes, with overall equipoise between the two therapies for new-onset MACE and a clear overall benefit with SGLT2i over GLP1-RA for new-onset heart failure and adverse kidney outcomes independent of differences in glycaemic efficacy (differences which themselves reflect differences in the clinical characteristics of individual patients). The gene discussed is GCG; the disease is heart failure.